| Ytd | 62.26% | |
| 1y | 131.60% |
| Open | 308.18 | Prev Close | 305.47 | Low | 302.74 | High | 308.18 | Mkt Cap | 6.12B |
| Vol | 39.08K | Avg Vol | 341.64K | EPS | 8.34 | P/E | 36.63 | Forward P/E | 34.01 |
| Beta | 1.10 | Short Ratio | 4.25 | Inst. Own | 107.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-02 | Earning | 08-06 | 50-d Avg | 263.66 | 200-d Avg | 215.63 | 1yr Est | 311.30 |
LGND News
Citigroup analyst Yigal Nochomovitz reinstates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy an
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest na
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor
Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f
B of A Securities analyst Jason Zemansky maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Bu
Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raise
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention t
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor
Ligand Pharmaceuticals (NASDAQ:LGND) affirms FY2026 Adj EPS guidance from $8.50-$9.50 to $8.50-$9.50
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which missed the
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, b
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) w
RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor
Ligand to acquire XOMA Royalty for $739 million, raising 2026 outlook as analysts maintain Buy ratin
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and XOMA Royalty Corporation ("XOMA Royalty
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and
HC Wainwright & Co. analyst Joseph Pantginis maintains Ligand Pharmaceuticals (NASDAQ:LGND) w
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeut
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and
Bank of America starts coverage on Ligand with a Buy rating and $244 target, citing strong royalty p
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r
B of A Securities analyst Jason Zemansky initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGN
Oppenheimer analyst Trevor Allred maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperfor
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday